Since the appearance of a positive ANA test in the serum may be slow to develop, it is crucially important to identify earlier biomarkers that may help to accurately establish which patients affected by Raynaud’s Phenomenon may be at risk of developing SSc before more serious clinical manifestations or internal organ involvement become apparent or before they develop clinical and pathologic SSc alterations. The gene discussed is BTG3; the disease is systemic sclerosis.